Recent News

• 06.09.2026 - Integrated by Design. Strategic pathways for drug-led combination products
• 06.04.2026 - Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
• 06.03.2026 - Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
• 05.28.2026 - Q4 & FY 2025 Earnings Conference Call & Webcast
• 05.28.2026 - ICON Reports Fourth Quarter and Full Year 2025 Results
• 05.27.2026 - ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
• 05.26.2026 - ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq
• 05.21.2026 - Reimagining vaccine development with AI

Recent Filings

• 06.05.2026 - 3 Initial statement of beneficial ownership of securities
• 06.05.2026 - 3 Initial statement of beneficial ownership of securities
• 05.27.2026 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 05.27.2026 - 6-K/A Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.27.2026 - EX-99.1 EX-99.1
• 05.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.26.2026 - EX-99.1 EX-99.1
• 05.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities